Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04981275 · ClinicalTrials.gov registry record
A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype
A clinical trial, sponsored by Onegevity Health.
- Completed
- Registry status
- 81
- Enrollment target
NCT04981275: Completed study, sponsored by Onegevity Health.
NCT04981275 is a clinical trial that has completed, run by Onegevity Health. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04981275 has completed, sponsored by Onegevity Health.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The purpose of this research study is to explore the relationship between the gut microbiome and hormone levels in women diagnosed with PCOS and determine whether there are differences in the gut microbiome between women with PCOS and women without PCOS. Consented, enrolled participants will complete a health questionnaire, complete a fasted blood draw at a local laboratory, and provide a stool, saliva, and vaginal swab sample for comprehensive biomarkers, hormones, metagenomics, and metabolomics analysis.
Primary Outcome
Understand phenotypical differences from biological samples comparing women with and without PCOS. Vaginal swabs are to be collected by women and analyzed with metagenomics and metabolomics sequencing.
Interventions
- OTHER No intervention study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-06-19 |
| Est. Completion | 2023-09-30 |
What the finished NCT04981275 record still lists
NCT04981275 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention study is the first listed.
NCT04981275 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04981275 about?
NCT04981275 is a clinical study titled "A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype". The purpose of this research study is to explore the relationship between the gut microbiome and hormone levels in women diagnosed with PCOS and determine whether there are differences in the gut microbiome between women with PCOS and women without PCOS. Consented, enrolled participants will comple...
What is the current status of trial NCT04981275?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2021-06-19. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT04981275?
The interventions under investigation include: No intervention study (OTHER).
Who is sponsoring clinical trial NCT04981275?
This trial is sponsored by Onegevity Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI